Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORAL-Boost: GRT-R910 samRNA Vaccine Boost
NCT05148962Phase 1Completed
- Sponsor
- Gritstone bio, Inc.
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- mRNA Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of GRT-R910 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Gritstone bio, Inc. Primary endpoints: Number of Participants With at Least One Solicited Local Adverse Event Within 8 Days After Prime Dose, Number of Participants With at Least One Solicited Local Adverse Event Within 8 Days After Booster Dose and 4 more. Started Sep 2021; status: completed.
02
Drugs
GRT-R910
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05148962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148962.